The new pressure injury and resident monitoring platform, developed by Lenexa Medical, is proving to reduce at-risk time and deliver efficiencies that improve quality of life for residents and peace of mind for families.
Developed in Australia, LenexaCARE® is a world first medical device for personalised pressure injury prevention. Consisting of a high-tech fabric-based sensor that can be fitted into any mattress and provide real time monitoring of a person’s position. The device also aids staff in repositioning residents and in planning turn schedules. Most importantly, when required the platform will alert carers nearby or at a remote station, enabling them to step in at the right time.
Pressure injuries (PIs) are mostly preventable; however, they remain a devastating complication for patients in hospital and residents in aged care settings, particularly where a person is immobile for a prolonged period. When a pressure injury advances to a deep wound, it can become life threatening or even fatal.
Research published in The International Journal of Nursing Studies (2022), reveals the systematic problem not only results in pain and suffering but costs the Australian health system over 9 billion dollars annually. Initial results from pilots have shown residents using LenexaCARE® are spending up to 67% less time in an at-risk position; indicating implementation would result in greatly reduced suffering as well as millions of dollars in cost savings for aged care providers, through reduced treatment costs and improved staff productivity.
“LenexaCARE® technology aids in the avoidance of painful pressure injuries and also takes the weight off carers bearing the load in an overburdened health system,” said Lenexa Medical Co-Founder and CEO Ajit Ravindran.
“The Lenexa system also provides carers with patient specific information to assist with individualised care and seamlessly integrates into existing nurse call systems.”
“Valley View is a 64-bed facility with many residents experiencing immobility due to disability or age-related issues,” Valley View CEO Mark Sheldon-Stemm.
“The LenexaCARE® technology will now support residents and staff with around the clock monitoring and provide our carers with resident specific insights and increased visibility of resident risk at any given time.”
“Valley View is leading the way launching the first roll out in Western Australia, but we can envisage this device integrated into healthcare systems across the globe,” Customer Feedback Systems Australasia (CFS) CEO Desmond McGuirk said.
“Improved medical outcomes for health organisations are always our goal, and we believe LenexaCARE is the light at the end of the tunnel for the global pressure injury problem.”